11 12, 2019

Spontaneous Ejaculation Induced with Atomoxetine

By |2019-12-11T13:47:25-08:00December 11th, 2019|Articles In Press|0 Comments

By Ferhat YAYLACI, Begüm ŞAHBUDAK, and Önder KÜÇÜK ABSTRACT Attention Deficit and Hyperactivity Disorder is one of the most common psychiatric disorders of childhood, characterized by attention deficit, hyperactivity and impulsivity. The most effective treatment in ADHD is drug treatment. Stimulant and nonstimulant drug treatments are preferentially used. Atomoxetine is [...]

11 12, 2019

Carotid Artery Dissection Induced Acute Tongue Swelling In A Cocaine User

By |2019-12-11T13:39:19-08:00December 11th, 2019|Articles In Press|0 Comments

By Antonio Siniscalchi, Paolo Perrotta, Piergiorgio Lochner, and Luca Gallelli ABSTRACT Carotid artery dissection represents a well-recognized cause of hypoglossal nerve paralysis even if it is less known the cause of acute tongue swelling. We report a 42-year old men who presented to our observation with acute tongue swelling and [...]

11 12, 2019

Efficacy Of Low-dose Aripiprazole For Treatment Of Psychotic Symptoms In A Patient With 22q11.2 Deletion Syndrome

By |2019-12-11T13:31:34-08:00December 11th, 2019|Articles In Press|0 Comments

By Konstantinos Kontoangelos, Eleni Lazaratou, Marina Economou, Konstantina G. Yiannopoulou ABSTRACT Objectives: The 22q11.2 deletion syndrome is one of the most prevalent genetic disorders and children suffering from this syndrome have been found to have a substantially greater risk for the development of schizophrenia and bipolar disorder. Psychiatric   medications such [...]

11 12, 2019

Asenapine In The Treatment Of Bipolar Depression

By |2019-12-11T12:31:49-08:00December 11th, 2019|Articles In Press|0 Comments

By Rif S. El-Mallakh, Sharon Nuss, Dong Gao, Yonglin Gao, Surriya Colleen Ahmad, MD;1 Clare Schrodt, and Caleb Adler ABSTRACT Objectives:  Asenapine, a potent serotonin 7 (5-HT7) receptor antagonist, was examined for efficacy as an antidepressant in depressed bipolar subjects.  It was predicted that subjects with the genetic variant of the short [...]

24 10, 2019

Dextromethorphan/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity

By |2019-10-24T09:38:15-08:00October 24th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Although currently available antidepressants increase monoamine levels soon after the start of treatment, therapeutic benefits are often delayed by several weeks and the majority of patients with major depressive disorder fail to achieve an adequate response to first- or second-line therapies targeting monoamines. The recent approval of the NMDA (N-methyl-d-aspartate) [...]

24 10, 2019

Over-the-Counter Device Offers Long-Lasting Pain Relief, New Data Shows

By |2019-10-24T09:28:34-08:00October 24th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

A novel, noninvasive, over-the-counter electromagnetic neuromodulation device (ActiPatch, BioElectronics Corp.) appears to deliver long-lasting relief in chronic pain patients. Results of a long-term prospective study that included 240 patients who had previously experienced chronic pain relief with the device showed that at 6 months, 97% of the 240 participants sustained [...]

29 07, 2019

Benefit Seen in the Use of Intranasal Insulin in Slowing Dementia

By |2019-07-29T16:49:18-08:00July 29th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Daily intranasal insulin may be effective in slowing progression of mild cognitive impairment (MCI) or Alzheimer's disease (AD), new research suggests. The findings were presented at the Alzheimer's Association International Conference (AAIC) 2019. Investigators found intranasal insulin administered via a novel delivery device slowed the rate of cognitive decline by [...]

28 03, 2019

Study Shows the Need for Psychiatric Care to be Integrated into Cancer Treatment

By |2019-03-28T14:15:40-08:00March 28th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Patients with prostate, bladder or kidney cancers are at greater risk of dying if they have had psychiatric care prior to the cancer treatment. In addition, patients with these cancers show greater suicide risk than the general population, even once the data is corrected for previous psychiatric care. These are [...]

21 03, 2019

Biogen, Eisai discontinue Alzheimer’s trials

By |2019-03-21T18:28:53-08:00March 21st, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

Biogen and Eisai have announced that they are discontinuing the ENGAGE and EMERGE trials, which were designed to test the efficacy and safety of aducanumab in patients with mild cognitive impairment caused by Alzheimer’s disease and mild Alzheimer’s disease dementia. The phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group trials were [...]

20 03, 2019

FDA Approves Brexanolone, First Drug for Postpartum Depression

By |2019-03-20T11:48:10-08:00March 20th, 2019|Brief Bulletins from the Field, We Know Psychiatry|0 Comments

The US Food and Drug Administration (FDA) has approved brexanolone intravenous infusion (Zulresso, Sage Therapeutics), the first-ever drug indicated for the treatment of postpartum depression. The drug is administered under medical supervision as a continuous infusion over a total of 60 hours (2.5 days), according to the FDA. Postpartum depression can [...]